Pink OG
An indica-leaning OG Kush relative known for pink-tinged buds, sweet-earthy aroma, and heavy sedating effects reported by users.
Pink OG is a decent-smelling, sedating OG Kush descendant that growers like because it's compact and finishes fast. Beyond that, most of what you'll read online is guesswork. Its lineage is undocumented, its cannabinoid and terpene numbers vary wildly between labs and phenotypes, and claims that it reliably treats insomnia or pain are based on user reports, not clinical trials. Treat the 'pink' name as marketing — cold-finished OGs often blush purple/pink regardless of pedigree.
Overview
Pink OG is a cannabis cultivar in the broader OG Kush family, marketed for its dense, often pink- or purple-tinged flowers and its heavy, body-forward effects. It circulates widely in North American dispensaries and seed catalogues, but no single breeder has an authoritative claim to the name — multiple seed banks sell versions of 'Pink OG' with different parents and different phenotypes Disputed.
Like most OG derivatives, it tends to smell of pine, earth, citrus rind, and a faint sweetness sometimes described as bubblegum or berry. The pink coloration is cosmetic: anthocyanin pigments in some cannabis chemotypes express more strongly at low temperatures late in flowering, and this happens across many unrelated cultivars [1] Strong evidence.
Chemistry: cannabinoids and terpenes
Reported THC content for Pink OG samples typically falls in the 16–24% range, with negligible CBD (<1%), consistent with most modern OG-family cultivars [2] Weak / limited. There is no peer-reviewed chemotyping study of Pink OG specifically; these figures come from dispensary and lab-report aggregates, which vary in methodology and rigor.
Terpene profiles reported for Pink OG samples most commonly show myrcene, β-caryophyllene, and limonene as the top three, with smaller amounts of linalool, α-pinene, and humulene Weak / limited. This pattern is typical for OG Kush descendants generally [3]. Be skeptical of any specific percentage claim tied to the strain name — terpene expression varies dramatically with phenotype, cure, and storage, and the same seed line grown in two rooms can produce noticeably different chemistry [4] Strong evidence.
The popular claim that a strain is 'an indica' because myrcene exceeds 0.5% is folklore with no scientific basis No data.
Reported effects
Users consistently describe Pink OG as sedating, physically relaxing, and appetite-stimulating, with effects skewing toward couch-lock at higher doses Anecdote. Common self-reported uses include help with sleep onset, pain, and stress relief.
Important caveat: there are no clinical trials on Pink OG, or on any specific cannabis cultivar sold under a strain name. Effects in a given person depend more on dose, THC:CBD ratio, terpene profile, route of administration, tolerance, and individual biology than on the marketing name [5] Strong evidence. Two batches of 'Pink OG' from different growers can produce meaningfully different experiences.
Expected side effects are the standard high-THC ones: dry mouth, dry eyes, dizziness, elevated heart rate, and — in sensitive users or at high doses — anxiety or paranoia [6] Strong evidence.
Lineage
Pink OG's parentage is not reliably documented Disputed. Several stories circulate:
- A cross of OG Kush × a pink/pheno-selected Kush cut, sometimes described vaguely as 'Pink Kush.'
- A backcross or selection out of Pink Kush itself (a separate Canadian-market cultivar).
- Simply an OG Kush phenotype that expressed pink pistils and got renamed.
None of these accounts trace back to a verifiable breeder record with dates and cut provenance. Cannabis lineage claims are notoriously unreliable in general because strain names are unregulated and genetically identical plants are frequently sold under different names, while genetically different plants are sold under the same name [7] Strong evidence. Treat any confident Pink OG family tree with skepticism.
Cultivation basics
Pink OG phenotypes sold commercially tend to share OG Kush growth traits: medium-short stature, moderate stretch after flip (roughly 1.5–2×), dense internodal spacing, and chunky, resinous buds that can be prone to bud rot in humid finishes Anecdote.
Practical notes reported by growers:
- Flowering time: 8–9 weeks indoor; slightly longer outdoors, typically finishing early-to-mid October in the Northern Hemisphere.
- Training: Responds well to topping, LST, and SCROG. Like other OGs, it appreciates strong support in late flower.
- Environment: Prefers moderate humidity (RH ~40–50% in flower) and good airflow to avoid mold in dense colas.
- Pink coloration: To coax the pink/purple expression, drop night temperatures by ~5–8 °C in the last two weeks of flower. Color is genetic-dependent — not every phenotype will blush regardless of temperature [1] Strong evidence.
Nutrient sensitivity and pest resistance are average for the OG family; no strain-specific agronomic studies exist.
Marketing vs. reality
What's real about Pink OG:
- It's a legitimate, widely-sold cultivar (or set of cultivars) in the OG family.
- Buds can genuinely turn pink or purple under the right conditions.
- Users reliably report sedating, body-heavy effects consistent with high-THC, myrcene-forward chemotypes.
What's marketing:
- The name. 'Pink' sells; the color is cosmetic and doesn't predict effects, potency, or lineage.
- Precise THC/terpene numbers on menus. These reflect a single lab test on a single batch, sometimes cherry-picked, and often produced under lab-shopping incentives that inflate reported THC [8] Strong evidence.
- Claims that it 'treats' insomnia, anxiety, or pain. No strain-specific clinical evidence exists. Cannabis broadly has evidence for chronic pain and some sleep uses [9] Strong evidence, but that evidence does not attach to a strain name.
- The indica/sativa label. The indica/sativa distinction does not reliably predict a plant's chemistry or a user's experience [10] Strong evidence.
Sources
- Peer-reviewed Docimo, T. et al. (2022). Molecular and Metabolic Bases of Flower Color and Pigmentation in Cannabis sativa. Frontiers in Plant Science.
- Peer-reviewed ElSohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., & Church, J. C. (2016). Changes in Cannabis Potency Over the Last 2 Decades (1995–2014). Biological Psychiatry, 79(7), 613–619.
- Peer-reviewed Smith, C. J., Vergara, D., Keegan, B., & Jikomes, N. (2022). The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE, 17(5), e0267498.
- Peer-reviewed Jin, D., Dai, K., Xie, Z., & Chen, J. (2020). Secondary Metabolites Profiled in Cannabis Inflorescences, Leaves, Stem Barks, and Roots for Medicinal Purposes. Scientific Reports, 10, 3309.
- Peer-reviewed Russo, E. B. (2019). The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis. Frontiers in Plant Science, 9, 1969.
- Government National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research.
- Peer-reviewed Schwabe, A. L., & McGlaughlin, M. E. (2019). Genetic tools weed out misconceptions of strain reliability in Cannabis sativa: implications for a budding industry. Journal of Cannabis Research, 1, 3.
- Peer-reviewed Jikomes, N., & Zoorob, M. (2018). The Cannabinoid Content of Legal Cannabis in Washington State Varies Systematically Across Testing Facilities and Popular Consumer Products. Scientific Reports, 8, 4519.
- Peer-reviewed Whiting, P. F. et al. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA, 313(24), 2456–2473.
- Peer-reviewed Piomelli, D., & Russo, E. B. (2016). The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis and Cannabinoid Research, 1(1), 44–46.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.